To All,
It's amusing to note that today, as the money managers much cajoled downturn is taking shape, that Van Kasper's coverage of NTII was pulled from the net, the NASDAQ dropped 11 points, and NTII's price jumped 20% on a volume upturn. One guess, for those who thrive on big money manipulation theories, is that the professionals want a quiet period during a market downturn to load up. The rest of that story would of course include renewed coverage just before a sweeping upturn, followed by another disapointing plunge (the big money of cousre wisely having sold again near the top. I guess this means I should sell as it hits 5, and wait or move on. Wish I really knew what was happening. I also wish I knew how much of a real company this is, and how much a get rich scheme by some ex-Cetus top managers and their venture capitalist enablers.(Always room for a few Charlie Chaplin's here, laughter is a good tonic). Clinical trials are among the most expensive part of the drug development process and this company is predictably grinding through the cash raised in those IPO's handled by Van Kasper. I would love to know how much is real here.Jeff Price, are you out there? But I have learned to set sell above X orders, not stops. At least last July taught me something! |
